Alternatively Spliced Landscape of PPARγ mRNA in Podocytes Is Distinct from Adipose Tissue

Claire Bryant 1, Amy Webb 2, Alexander S. Banks 3, Dawn Chandler 4,5, Rajgopal Govindarajan 6,7 and Shipra Agrawal 1,5,8,*

1 Center for Clinical and Translational Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA
2 Department of Bioinformatics, The Ohio State University, Columbus, OH 43210, USA
3 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
4 Center for Childhood Cancer and Blood Disease, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA
5 Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
6 Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
7 Translational Therapeutics, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
8 Division of Nephrology and Hypertension, Department of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
* Correspondence: shipra.agrawal@stonybrookmedicine.edu

Abstract: Podocytes are highly differentiated epithelial cells, and their structural and functional integrity is compromised in a majority of glomerular and renal diseases, leading to proteinuria, chronic kidney disease, and kidney failure. Traditional agonists (e.g., pioglitazone) and selective modulators (e.g., GQ-16) of peroxisome-proliferator-activated-receptor-γ (PPARγ) reduce proteinuria in animal models of glomerular disease and protect podocytes from injury via PPARγ activation. This indicates a pivotal role for PPARγ in maintaining glomerular function through preservation of podocytes distinct from its well-understood role in driving insulin sensitivity and adipogenesis. While its transcriptional role in activating adipokines and adipogenic genes is well-established in adipose tissue, liver and muscle, understanding of podocyte PPARγ signaling remains limited. We performed a comprehensive analysis of PPARγ mRNA variants due to alternative splicing, in human podocytes and compared with adipose tissue. We found that podocytes express the ubiquitous PPARγ Var1 (encoding γ1) and not Var2 (encoding γ2), which is mostly restricted to adipose tissue and liver. Additionally, we detected expression at very low level of Var4, and barely detectable levels of other variants, Var3, Var11, VartORF4 and Var9, in podocytes. Furthermore, a distinct podocyte vs. adipocyte PPAR-promoter-response-element containing gene expression, enrichment and pathway signature was observed, suggesting differential regulation by podocyte specific PPARγ1 variant, distinct from the adipocyte-specific γ2 variant. In summary, podocytes and glomeruli express several PPARγ variants, including Var1 (γ1) and excluding adipocyte-specific Var2 (γ2), which may have implications in podocyte specific signaling and pathophysiology. This suggests that new selective PPARγ modulators can be potentially developed that will be able to distinguish between the two forms, γ1 and γ2, thus forming a basis of novel targeted therapeutic avenues.

Keywords: PPARγ; podocyte; glomerular disease; proteinuria; alternative splicing

1. Introduction

Thiazolidinediones (TZDs) or peroxisome proliferator activated receptor γ (PPARγ) agonists such as pioglitazone, directly protect podocytes from injury as demonstrated in podocyte culture in vitro studies [1–5], and reduce proteinuria and glomerular injury...
in various animal models of glomerular disease, as reported in preclinical in vivo studies [5–13]. Moreover, these beneficial effects of PPARγ have been shown to be mediated by activation of podocyte PPARγ as demonstrated by elegant studies using podocyte specific Pparg knock out (KO) mouse model [7,10]. This indicates a pivotal role for PPARγ in maintaining glomerular function through preservation of podocytes [1,5–7,10]. Podocytes are highly differentiated epithelial cells in the kidneys, whose structural and functional integrity is critical for the maintenance of glomerular filtration barrier [14–16]. Accordingly, their dysfunction or loss is the initiating and progressing characteristic factor in a vast majority of renal diseases, leading to chronic kidney disease and kidney failure. Glomerular diseases characterized by high proteinuria manifest as nephrotic syndrome (NS) which is often associated with co-morbidities such as hypoalbuminemia, hypercholesterolemia, edema, and hyper-coagulopathy [17–23]. Recently, our group has further demonstrated that selective modulation of PPARγ with a partial agonist, GQ-16, provides high efficacy in reducing proteinuria, as well as NS-associated comorbidities in an experimental model of nephrotic syndrome [24]. Thus, a multitude of evidence shows that targeting the podocyte PPARγ pathway offers an attractive therapeutic strategy in NS. While PPARγ has an established role in driving many adipogenic and lipid metabolizing genes mainly in adipose tissue, liver, and muscle, the understanding of molecular pathways regulated by PPARγ in podocytes and glomeruli remains limited [5–7,9,10,25–29]. Furthermore, it is well-known that PPARγ exists in two major isoforms, γ1 and γ2, which are a result of different promoter usage as well as alternative splicing (AS) [5,30,31]. As a result, γ2 contains 30 additional amino acids at its N terminal, despite a longer mRNA sequence towards the 5’UTR of γ1. While γ1 is more widely expressed, γ2 is mostly restricted to adipose tissue and liver. Few other forms have been discovered, including some with dominant negative function [32–37]. Moreover, cell-specific expression of PPARγ variants has been demonstrated to play a differential role in downstream gene expression pattern in adipocytes (expressing the γ2 variant) vs. the macrophages (expressing the γ1 variant) [38]. However, the specific variant or isoform(s) expression of PPARγ and the role of its AS in podocytes and glomerular disease is unexplored. In this study, we sought out to answer this critical gap in the literature by hypothesizing that alternative splice variants of PPARγ expressed in podocytes are distinct from adipocytes. To address this hypothesis, we performed a comprehensive analysis of different AS variants of PPARγ in human podocytes and studied the expression of γ1 vs. γ2 variant in podocyte vs. adipose tissue in detail.

2. Materials and Methods

2.1. Podocyte Cell Culture and Treatments

Immortalized human podocytes were cultured in RMPI 1640 (Corning, Tewksbury, MA, USA) supplemented with 10% fetal bovine serum (FBS) (Corning, Tewksbury, MA, USA), 1% 100 X Penicillin Streptomycin L-Glutamine (PSG) (Corning, Tewksbury, MA, USA), and 1% Insulin-Transferrin-Selenium-Ethanolamine (ITS-X) (Gibco, Gaithersburg, MD, USA) [39]. Proliferating podocytes were cultured in a humidified atmosphere with 5% CO₂ at 33 °C and the media was changed twice per week and cells were passaged at ~70–80% confluence. Differentiation was induced by placing the cells at 37 °C under the same atmospheric conditions, for 14 days. Differentiated cells were treated with puromycin aminonucleoside (PAN) (Sigma-Aldrich, St. Louis, MO, USA) at 25 µg/mL or with pioglitazone (Alfa Aesar, Tewksbury, MA, USA) at 10 µM. Control cells received treatment of vehicle dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA). Cells were harvested after 24 h and total RNA isolated.

2.2. Kidney, Liver and Adipose Tissues

This study was approved by the Institution Animal Care and Use Committee at Nationwide Children’s Hospital and the experiments were performed according to their guidelines. Male Wistar rats weighing ~150–200 g (Envigo, Indianapolis, IN, USA) were purchased, acclimated for 3 days, and housed under standard conditions. They were
sacrificed to collect kidneys, liver, and white adipose tissue (WAT) epididymal fat. Tissues were flash frozen in liquid nitrogen prior to RNA isolation. Glomeruli were isolated from harvested kidneys using the sequential sieving method as previously described [24] and total RNA was isolated. Commercially available human and rat kidneys total RNA was purchased from Zyagen (San Diego, CA, USA).

2.3. RNA Isolation

Rat epididymal fat and liver tissue samples were lysed in RNA extraction buffer (RLT) from the RNeasy kit (Qiagen, Germantown, MD, USA) with stainless-steel disruption beads for 4 min at 30.0 Hz using the Qiagen TissueLyser (Germantown, MD, USA). Total RNA was immediately isolated from the lysate using the RNeasy kit (Qiagen, Germantown, MD, USA), following the manufacturer’s instructions. Total RNA was extracted from rat glomeruli tissue and human podocyte samples using the mirVanaTM Isolation Kit (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. RNA yield and purity was checked prior to downstream applications by measuring the absorbance at 260, 280, and 230 nm with a nanodrop spectrophotometer (ThermoFisher, Waltham, MA, USA) and by calculating appropriate ratios (260/280, 260/230).

2.4. DNase Treatment, cDNA Synthesis, and PCR

Total RNA was DNase treated according to manufacturer’s instructions (Zymo Research, Irvine, CA, USA). 500 ng–1 µg DNase-treated RNA was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instruction and the resulting cDNA was used for reverse transcription-polymerase chain reaction (RT-PCR) using HotStarTaq Plus Master Mix Kit (Qiagen, Germantown, MD, USA). The PCR conditions used were as follows: 95 °C for 5 min, 40 cycles [95 °C for 30 s, 50–60 °C (depending on the primer pair) for 30 s, 72 °C for 30 s], hold at 4 °C. Housekeeping gene RPL6 was amplified only for 28 cycles to prevent over-saturation. The PCR-products were separated on a 1.5–2.5% agarose gel along with molecular weight ladder (ThermoFisher, Waltham, MA, USA), stained with 0.5 µg/mL ethidium bromide (Research Products International, Mount Prospect, IL, USA), and images were captured using the Chemidoc (Bio-Rad, Hercules, CA, USA) equipment. Densitometry was performed using ImageJ Software (National Institutes of Health, Bethesda, MD, USA) and band density was calculated by subtracting background and normalizing to RPL6. Quantitative RT-PCR (qRT-PCR) was performed on samples using SYBR green (Bio-Rad, Hercules, CA, USA) on the Applied Biosystems 7500 Real-Time PCR System (Waltham, MA, USA). The PCR conditions were 95 °C for 10 min, 40 X (95 °C for 15 s, 50–60 °C for 1 min) followed by a melt curve to ensure specific products. Analysis was performed using the ∆∆Ct method [40] with normalization to RPL6.

2.5. Primer Design and Synthesis

Primers were custom designed to detect various PPARγ variants for alternatively spliced mRNA products using the Reference Sequence Database (National Center for Biotechnology Information, Bethesda, MD, USA) and confirmed for the potential binding transcripts in the annotated database using the Primer Blast program (National Center for Biotechnology Information, Bethesda, MD, USA) (Table 1, Figure 1A). For variants with exon skipping, primers were designed to span the exon-exon junction to create a specific primer pair that would exclusively amplify the desired mRNA variant.
Figure 1. Alternatively Spliced Variants and Isoforms of PPARγ in Podocytes. (A) The schematic depicts the exon and intron usage and the transcription and translation start and stop sites for various PPARγ variants. The major isoforms of PPARγ are isoforms γ1 and γ2, which encode for proteins containing 475 and 505 amino acids, respectively. The most common human annotated variants 1 (var1: NM_138712) and 2 (var2: NM_015869) encode isoforms γ1 and γ2 (depicted in the topmost PPARγ illustration). These two variants are transcribed by different promoter usage by RNA Polymerase II (depicted in tall arrows) and alternative splicing (depicted by exon skipping). PPARγ1 variant 1 includes exons A1 and A2, a start codon (ATG) on exon 1, and γ2 variant 2 excludes exons A1 and A2, but includes exon B and a start codon in the same exon B. Thus, γ1 protein product is 30 amino acids shorter than γ2. The less known and understood variants are represented below, which include Variants 3, 4, 11, 9 and tORF4/Var 10. These are depicted with A1 and A2 usage in the schematic to emphasize those likely to be expressed in podocytes, although their adipocyte counterparts with exon B usage at the 5’ UTR also exist. A1 and A2 exons are shown in light blue, exon B in dark blue, internal exons are in green boxes, introns are black lines, spliced out exons are marked with blue lines. Primer pairs used to amplify major variants and other variants are depicted in grey arrows and circles (A1, Ex1, a–j, Table 1). For the variants that skip an exon, the primer spans the exon-exon junctions and is shown as a split grey arrow underneath the introns (c, g, i). Protein isoforms are shown below their corresponding RNA in purple and amino acid (aa) length is listed. (B) Summary of the protein isoforms (γ) and RNA variants (var) with detailed exon/intron usage and annotations. γ2 is found primarily in adipose tissue, while γ1 is found in podocytes. Variants 1, 3, and 4 are variants of γ1 that are likely to be found in podocytes, while variants 9, 10, and 11 are
additional less explored variants that would encode different isoforms. The variant 10 version of tORF4 is annotated that contains exon A1.2, but there is not an annotated version of tORF4 that would contain exon A1. (C) A representative gel showing the expression of several variants of PPARγ in differentiated podocytes. PCR products were generated using specific primer pairs and run on an agarose gel and stained with ethidium bromide. All PPARγ [primer pair Ex1 F, aR; 315 bp]; γ2 [primer pair bF, aR; expected product 476 bp]; variants 1, 9, 11 (432 bp PCR product) and Var 4 (358 bp product) [doublet primer pair, A1F, aR]; variants 3, 5, and 10 (415 bp product); variant 7 (341 bp product); and variant 12 (503 bp product) [primer pair dF, aR]. Primers are listed in Table 1.

Table 1. Primers Used in the Current Study.

| Name                | Species          | Forward                      | Reverse                   |
|---------------------|------------------|------------------------------|---------------------------|
| **PPARγ**           |                  |                              |                           |
| Total (All)         | Homo Sapiens     | ATGACCATGGTGACACACG Ex1      | GGAGTTGGAAGGCTTTCAT A     |
| Doublet             | Homo Sapiens     | CGAGGACACCCGGAGAGGG A1       | GGAGTTGGAAGGCTTTCAT A     |
| Var2 (γ2)           | Homo Sapiens     | TTTAAACCGATGGTACTTTTG b      | GGAGTTGGAAGGCTTTCAT A     |
| Var1 (γ1)           | Homo Sapiens     | GAAAGAAGCCACACTAACCACac      | GGAGTTGGAAGGCTTTCAT A     |
| Var3 (γ1)           | Homo Sapiens     | TTCTGCTTAATTCCTTTTC d        | GGAGTTGGAAGGCTTTCAT A     |
| Var4 (γ1)           | Homo Sapiens     | GCGCGCCGTGGCCGAGAAAAe        | GGAGTTGGAAGGCTTTCAT A     |
| Var11 (γ3)          | Homo Sapiens     | TTTCGAGTGGGATGCTTCA f        | CAGCAAACTGCGGGTGTTGA g    |
| Var9 (γ5)           | Homo Sapiens     | AGAGCCTTCAACTCTTTCA h        | GTTACGATGAACTTGCCAT I     |
| tORF4               | Homo Sapiens     | AGAGGCTTCAACTCTTTCA h        | AAAACAAAAACATCTCCCG j     |
| Var1 (γ1) *         | Rattus Norvegicus| GAAAGAAGCTTGGACACACT Rat c   | GGAGTTGGAAGGCTTTCAT Rat a |
| (γ2) *              | Rattus Norvegicus| GCACCTCACAAGAAATTACC Rat b   | GGAGTTGGAAGGCTTTCAT Rat a |
| Total (All) *       | Rattus Norvegicus| ATTACCATGGTGACACAG Rat Ex1   | GGAGTTGGAAGGCTTTCAT Rat a |

**Podocyte Specific Genes**

| Name                | Species          | Forward                      | Reverse                   |
|---------------------|------------------|------------------------------|---------------------------|
| NPHS1               | Homo Sapiens     | CGCAGGAGGAGGTGTCTTATTC       | CCGGTTCAGAGGTCTCAGAG     |
| Nphs1               | Rattus Norvegicus| TGCTTTTTCAGTGGTCTCTCA       | TCTGATGCTGCTCTCCGAC      |
| SYNPO               | Homo Sapiens     | AGGTAGGCGTGGAGGAGG           | GAGGTTCGCTGTTGGTTTGG     |
| Synpo               | Rattus Norvegicus| CGCCTTGGGTCCCCCTTC           | TGAACCTGTCACCTCTGC       |
| WT1                 | Rattus Norvegicus| CCCTACAGCAGTGACAATTTTAC      | TGCCCTTCTGTCATTTTC       |

**Adipose Tissue Specific Genes**

| Name                | Species          | Forward                      | Reverse                   |
|---------------------|------------------|------------------------------|---------------------------|
| CD36                | Homo Sapiens     | GAGACTGCGATGTAGACTATTTCC     | TCCGGTGACAGCCCATTTT       |
| Cd36                | Rattus Norvegicus| AAGTTATAGCGCACATGATT         | GATCCAAAACACAGCATGAT     |
| ADIPOQ              | Homo Sapiens     | ACTGCAGTCTGTGGTCTGA          | ACTCGGTTGTCAGCGATG       |
| Adipoq              | Rattus Norvegicus| TGTTTCTTCTAACTCTGCGCA        | CCAACCTGCAAGATTTCCTT     |
| ADIPSIN             | Homo Sapiens     | CCCCGGCTGGTGCCGAT            | GACAGCTGTGACAGCAGAG      |
| Adipsin             | Rattus Norvegicus| AAGCCTTCCCCACATCGCCT         | CATGGTCATGTCGCCAGATTG    |
| AP2                 | Homo Sapiens     | AAAGTCAAGAGCACCATAACCTT     | TGACGCCCTCTGATGCACTTCC   |
| Ap2                 | Rattus Norvegicus| AAAGTGAAGAGCATACAACTCTC     | TCACGCTTTCTGATGCACTTCC   |

**Housekeeping Genes**

| Name                | Species          | Forward                      | Reverse                   |
|---------------------|------------------|------------------------------|---------------------------|
| GAPDH               | Homo Sapiens     | AGACACCATGGGGAAGGTTGA        | GACGTTGGCATTGGAATTTGC     |
| RPL6                | Homo Sapiens     | GCAACCCGTCTCGTCTGCAAGA       | GCCACCTGCTTCAAGAAAAAC     |
| Rpl6                | Rattus Norvegicus| AGGCATCAGAGGGTGAGAT          | TGTAAGGTAATTCGCTCTCC    |

* Rat nomenclature is annotated differently than human γ1 and γ2 variants. Primers a–j, Ex1, A1 are depicted in Figure 1A. Rat primers correspond to locations listed for human primers in Figure 1A.
2.6. PPAR-Promoter Responsive Element Prediction

Bulk RNAseq datasets from untreated control differentiated human immortalized podocytes (GEO GSE124622) [41] and untreated control differentiated human adipocytes (GEO GSE129153) [42] were analyzed. The average expression of control samples from the aforementioned GEO datasets were calculated and normalized expression greater than 2 were counted as detected. Genes were further cross referenced against the verified target and predicted PPAR Response Element (PPRE) genes that were downloaded from PPARgene database (http://www.ppargene.org/downloads.php (accessed on 31 July 2022)) [43] and using computational genomics approach [44]. Key podocyte and adipocyte specific genes measured in this study were also queried through the PPAR gene database (ppargene.org) to predict PPAR-responsive elements (PPRE) on their promoters. Upon query submission, p-value and confidence level were generated if the gene was predicted as a PPAR target gene and contained putative PPREs in the 5 kb transcription start site flanking region. They were assigned into categories of confidence as: high (\(p > 0.8\)), medium (0.8 \(\geq p > 0.6\)), and low (0.6 \(\geq p > 0.45\)). A \(p\) value \(\leq 0.45\) was predicted as negative. Functional annotation of PPRE containing genes detectable exclusively in adipocytes vs. podocytes were performed using clusterProfiler (RRID:SCR_016884) [45] and plotted as many as 10 terms per cell type. The PPRE containing genes detectable in adipocyte vs. podocytes the overlapping genesets, and the associated functional terms were also compared.

2.7. Statistical Analysis

Statistical analysis was performed using GraphPad Prism Software version 8.2.0 for Windows (GraphPad Software, San Diego, CA, USA). Data are expressed as mean ± standard error of mean and compared using unpaired Student’s t-test. \(p\) value significance is depicted as * \(p < 0.05\), ** \(p < 0.01\), **** \(p < 0.0001\).

3. Results

3.1. Podocyte Specific PPARγ Splice Variants

To identify the PPARγ variants expressed in podocytes and to elucidate differences in podocytes vs. adipocytes, we examined the known variants of PPARγ by reviewing the literature, scoping out the annotated versions (RefSeq database, NCBI), and by performing variant specific PCRs using custom-designed primers. A schematic of different variant forms (Figure 1A) and their exon/intron usage information and annotation (Figure 1B) is presented. Conducting PCR utilizing variant-specific primer pairs (Figure 1A and Table 1), we could identify total PPARγ expression, specific variants corresponding to γ1 (Var1 and 4) and other forms in differentiated podocytes, but not the γ2 form (Var 2) (Figure 1C), which is highly expressed in differentiated adipocytes [46]. Variant 2 (encodes γ2, a protein of 505 amino acids) includes exon B which contains a start codon. Variant 1 (encodes γ1, a protein of 475 amino acids) utilizes exons A1 and A2 instead of B in the 5'UTR of the gene, resulting in the usage of a start codon ATG located on exon 1. Variants 3 and 4 both encode γ1 as well, but they have differing 5'UTRs. Variant 3 contains an alternative exon A1.2, and variant 4 skips exon A2. Variant 11 has a similar 5'UTR to variant 1, but it skips exon 5, resulting in a frameshift and a premature stop codon in exon 6, encoding a potential product of 248 amino acids (γ3). Variant 9 utilizes a start codon located in exon 3 and skips exon 4, encoding γ5 (266 amino acids). Variant 10 or tORF4 uses a partially retained intron after exon 4 which contains a stop codon, making a product of 266 amino acids (γ6). Variant 10 version of tORF4 is annotated and contains exon A1.2, but there is no annotated variant that uses exon A1. The possibility of expression of other variants was considered using primer pairs that would amplify specific products (Figure 1C). The doublet primer pair was able to discriminate between the cumulative expression of variants 1, 9 and 11 vs. variant 4. Cumulative expression of variants 3, 5, 7, 10 and 12 was ruled out using primer pair for Var3 (dF and aR), which would also amplify these other mentioned variants.
3.2. PPARγ Splice Variants in Podocytes vs. Adipose Tissue

PPARγ

PPARγ is a transcription factor and an established master regulator of fat cell physiology and differentiation in adipose tissue and liver [28,47]. While podocyte specific Pparg KO mice illustrated its role in podocytopathies [7,10], to understand the cell- and tissue-specific determinants of PPARγ function in glomeruli and in podocytes, we performed specific PCRs to detect the expression of total (all) variants and exclusively of variant 1 (encoding γ1) and variant 2 (encoding γ2) in human podocytes and whole kidney and rat tissues of glomeruli, whole kidney, liver and WAT. In accordance with the hypothesis of cell specific action of PPARγ, while expression of variant encoding the PPARγ2 isoform was observed in WAT, liver, and whole kidneys, γ2 variant was undetected in human podocytes and in the rat glomeruli (Figure 2A). As shown in Figure 1A, γ1 and γ2 use different, promoter sites and undergo AS. Expression analysis of several uncommon variants described in Figure 1 demonstrated that they are present at low and varying levels in the whole human kidney (Figure 2B). Most of these (variants 4, 3, 11, 9, and tORF4) were found to be expressed at very low to undetectable levels in podocytes (Figure 2B). Moreover, analysis of the variants encoding γ1 (Var 1 and 4) showed that their levels remained unchanged with PAN-induced injury of podocytes or treatment with PPARγ agonist, pioglitazone (Figure 2C).
Figure 2. Expression of PPARγ Splice Variants in Podocytes vs. Adipose Tissue. (A) Total RNA was isolated from glomeruli, liver, and WAT samples harvested from rats, and from cultured differentiated human podocytes. Expression of the RNA variants encoding PPARγ1 and γ2 (All variants), γ1 only (Var1), and γ2 only (Var 2) isoforms was measured by RT-PCR in isolated samples as well as commercially available human and rat whole kidney RNA. Rat total (all) γ [primer pair ex1 F, ex 2 R; 315 bp], rat γ1 [primer pair exA2 F, ex2 R; 380 bp], rat γ2 [primer pair exB F, ex2 R; 329 bp], rat Rpl6 [178 bp], human total (all) γ [primer pair Ex1 F, aR; 315 bp], human γ1 [primer pair cF, aR; 387 bp], human γ2 [primer pair bF, aR; 476 bp], Human RPL6 [370 bp]. (B) Several PPARγ mRNA AS variants were analyzed by RT-PCR in cultured differentiated human podocytes and commercially available human whole kidney RNA using the primer pairs drawn in Figure 1A and detailed in Supplementary Table S1. Var1 [primer pair cF, aR; 387 bp], Var3 [primer pair dF, aR; 415 bp], Var4 [primer pair eF, aR; 333 bp], Var11 [primer pair fF, gR; 242 bp], Var9 [primer pair hF, iR; 254 bp], tORF4 [primer pair hF, jR; 490 bp], Total [primer pair Ex1 F, aR; 315 bp], RPL6 [370 bp] (C) Expression of PPARγ mRNA variants 1 [primer pair cF, aR] and 4 [primer pair eF, aR], as well as total (All) PPARγ [primer pair Ex1 F, aR] and GAPDH in puromycin aminonucleoside (PAN)-injured and pioglitazone-treated podocytes. Primers are listed in Table 1.
3.3. PPAR-Response Element (PPRE) Containing Genes in Podocyte vs. Adipocyte

PPARγ binds to its promoter response elements (PPRE) along with other transcription factors such as retinoid X receptor (RXR) or to other DNA elements in association with factors such as nuclear factor kappa B (NFκB), activator protein 1 (AP1), and in proximity to CCAAT enhancer-binding proteins (C/EBPα) [5,25,38]. We carried out promoter element prediction using a PPARgene database (ppargene.org (accessed on 31 July 2022)) [43] and cross-referenced it with bulk RNASeq GEO datasets obtained from control podocytes (GSE124622) [41] and adipocytes (GSE129153) [42]. We found that while 1669 PPRE-containing genes were detectable in both podocyte and adipocyte datasets, 453 were found to be unique to podocytes and 77 unique to adipocytes (Figure 3A(i), Supplementary Table S1). These were further classified into subsets based on the confidence level of PPRE prediction (see Methods; Figure 3A(ii)). We further analyzed a select set of PPRE containing genes known to play critical roles in podocyte pathophysiology, such as NPHS1 (nephrin), SYNPO (sympatopodin), and WT1 (wilms tumor 1) or those that have established roles in adipogenesis, such as CD36, ADIPOQ, ADIPSIN, and AP2 [29,47–52] (Table 2). All the adipogenic genes depicted high level of PPRE prediction, and NPHS1, SYNPO, and WT1 showed low to high levels of PPRE prediction. These genes which are known to play prominent roles in podocytes vs. adipocytes correlated with their expression in the GEO datasets in podocytes vs. adipocyte. In accordance, we also observed a marked disparity in the expression of these genes in podocytes vs. white adipose tissue (WAT) (Figure 3B). While the podocyte markers (NPHS1, SYNPO and WT1) are expressed at a higher level in podocytes vs. adipose tissue, expression of adipokines (ADIPOQ and ADIPSIN) and adipogenic genes (CD36 and AP2) was found to be high in WAT and absent or modestly expressed in podocytes (Figure 3B, Table 2). Furthermore, functional enrichment analysis of PPRE-containing genes exclusive to podocyte or adipocyte generated distinct maps of biological processes, cellular components, molecular functions and pathways (Figure 3C–F).

In summary, this data suggests the existence of a PPRE-containing gene expression, enrichment and pathway signature that is distinct in podocytes vs. adipocytes. This is likely driven by podocyte specific γ1 form of PPARγ vs. the adipocyte-specific γ2 form.
Figure 3. PPARγ-Response Element (PPRE) Containing Genes in Podocytes vs. Adipocytes. (A) Normalized average log counts of untreated control human differentiated podocyte and adipocyte GEO datasets (GSE124622 and GSE129153, respectively) were cross-referenced against the verified target and predicted PPRE genes from the PPARgene database. (i) 1669 PPRE-containing genes were detectable in both podocyte and adipocyte datasets, 453 unique to podocytes and 77 unique to adipocytes. (ii) PPRE-containing genes classified by their confidence level. High-confidence ($p > 0.8)$, median-confidence ($0.8 \geq p > 0.6$), low-confidence category ($0.6 \geq p > 0.45$). Genes with $p$ value $< 0.45$ were predicted as negative. (B) Total RNA was isolated from cultured differentiated human podocytes and WAT harvested from rats. Expression of the podocyte marker genes (NPHS1 [Hu: 234 bp, Rat: 138 bp], SYNPO [Hu: 182 bp, Rat: 325 bp], and WT1 [Hu/Rat: 134 bp]) and adipose tissue genes (CD36 [Hu: 304 bp, Rat: 123 bp], ADIPOQ [Hu: 347 bp, Rat: 95 bp], ADIPSIN [Hu: 301 bp, Rat: 202 bp], and AP2 [Hu: 133 bp, Rat: 133 bp]), and housekeeping gene RPL6 [Hu: 370 bp, Rat: 178 bp] were analyzed. (i) Representative gels depicting the PCR products of key genes in podocytes and adipocytes. (ii) – iii) Quantitative mRNA fold-changes measured and graphically presented using RT-PCR and real time qRT-PCR quantification of key genes in podocytes vs. adipocytes. (C–F) clusterProfiles generated functional enrichment of PPRE containing genes detectable exclusively in adipocytes (77) vs. podocytes (453) and plotted as 10 terms per cell type for (C) biological processes, BP, (D) cellular components, CC, (E) molecular functions, MF, and (F) kyoto encyclopedia of genes and genomes, KEGG. The color of the dot indicates the intensity of adj $p$ value (smaller adj $p$ value is more red) and size of the dot indicates the proportion of genes from the term that are present in the cell-specific PPRE containing genes. * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$. 

| PPRE Confidence | Podocyte Only | Adipocyte Only | Both |
|-----------------|---------------|----------------|------|
| High            | 62            | 12             | 323  |
| Medium          | 142           | 26             | 511  |
| Low             | 241           | 35             | 811  |
Table 2. Expression of Select PPRE Containing Genes.

| Gene          | Cells/Tissue Tested in the Current Study | p Value a | Confidence Level | PPREs Predicted b | Podocyte Count log c | Adipocyte Count log d (Normalized) |
|---------------|-----------------------------------------|-----------|------------------|-------------------|----------------------|-----------------------------------|
| Podocyte Prominent Genes |                                        |           |                  |                   |                      |                                   |
| Nphs1         | Podocyte/WAT                            | 0.63696   | Medium           | 4                 | 2.27                 | –                                 |
| Synpo         | Podocyte/WAT                            | 0.8715    | High             | 5                 | 7.89                 | 9.03 (1.3)                       |
| Wt1           | Podocyte/WAT                            | 0.55556   | Low              | 5                 | 4.91                 | –                                 |
| Adipocyte Prominent Genes |                                    |           |                  |                   |                      |                                   |
| Cd36          | Podocyte/WAT                            | 0.97886   | High             | 3                 | 3.77                 | 846.26 (117.2)                  |
| Adipoq        | Podocyte/WAT                            | 0.97153   | High             | 12                | 2.59                 | 112.19 (15.5)                   |
| Adipsin       | Podocyte/WAT                            | 0.96216   | High             | 6                 | 4.22                 | 991.32 (137.3)                  |
| Ap2/Fabp4     | Podocyte/WAT                            | 0.99997   | High             | 10                | –                    | 1663.6 (230.5)                  |
| Housekeeping  |                                        |           |                  |                   |                      |                                   |
| Rpl6          | Podocyte/WAT                            | –         | –                | –                 | 13.42                | 96.86 (13.42)                   |

a Probability of PPAR target gene, higher value means a higher confidence. High-confidence (p > 0.8), median-confidence (0.8 ≥ p > 0.6), low-confidence category (0.6 ≥ p > 0.45). Genes with p value ≤ 0.45 were predicted as negative. b Putative PPREs in the 5Kb transcription start site (TSS) flanking region. c Podocyte GEO Dataset # GSE124622. d Adipocyte GEO Dataset # GSE129153.

4. Discussion

PPARγ agonism has a well-established beneficial role in the setting of diabetes, which has led to the generation of TZDs for the treatment of type II diabetes (Figure 4) [53,54]. Its beneficial role in kidney cells beyond its favorable systemic metabolic effects in diabetes originated from numerous preclinical studies and meta-analyses [55–59]. Earlier these effects of PPARγ in influencing non-diabetic glomerular disease was thought to be through its anti-inflammatory actions on endothelial and myeloid cells [60–62]. However, recent discoveries and advances suggest the role of podocytes in mediating these effects. Seminal studies from our group and other research teams suggested that TZDs such as pioglitazone, directly protect podocytes from injury [1–5] and reduce proteinuria and glomerular injury in various animal models of glomerular disease [5–13] (Figure 4). Moreover, studies using podocyte specific Pparγ KO mouse demonstrated that the beneficial effects of PPARγ are mediated by activation of podocyte PPARγ, thus indicating a pivotal role for PPARγ in maintaining glomerular function through preservation of podocytes [1,5–7,10]. However, the specific variant or isoform(s) expression of PPARγ and the role of its AS in podocytes and glomerular disease is unexplored. We hypothesized that AS variants of PPARγ expressed in podocytes are distinct from adipocytes. We addressed this hypothesis by performing a comprehensive analysis of different AS variants of PPARγ in human podocytes and by studying the expression of γ1 vs. γ2 variant in podocyte vs. adipose tissue in detail. Our findings suggest that the podocytes mainly express the γ1 form, along with minimal expression of other AS forms. They do not express the γ2 form, yet they are responsive to treatments by PPARγ agonists, implicating that new selective modulators can be potentially developed that will be able to distinguish between the two forms, γ1 and γ2, thus forming a basis of novel targeted therapeutic avenues.
Figure 4. Illustration Describing the Roles of PPARγ1 and 2 Isoforms. Schematic of the suggested roles of PPARγ 1 and 2 forms in regulating podocyte/glomerular disease specific effects (right panel) vs. metabolic/systemic and adipogenic effects (left panel). PPARγ agonism plays a well-established role in the setting of treatment of Type II Diabetes, and treatment with its agonists, thiazolidinediones (TZDs), leads to increased (‘a’ pathway) insulin sensitivity and glycemic control [53,54]. However, these beneficial effects are also accompanied with adverse effects (‘a’ pathway), such as increased cholesterol, adipogenesis and decreased osteoblastogenesis [25]. TZDs or PPARγ agonists have now been demonstrated to reduce podocyte injury (‘b’ pathway) by enhancing their viability and cytoskeletal integrity and decreasing apoptosis [1–5]. A few pathways involved in this process include crosstalk with the glucocorticoid receptor (GR), decreased caspase-3 activity and decreased TRPC6 expression. Gain of PPARγ activity or its activation by TZDs (‘c’ pathway) has been shown to reduce proteinuria and glomerulosclerosis in various animal models of glomerular disease, such as 5/6 nephrectomy (Nx), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and glomerulonephritis (GN) [5–13,24]. On the other hand, loss of PPARγ in podocyte specific Pparg KO mouse (‘d’ pathway) has demonstrated exacerbation of glomerular injury and proteinuria in animal disease models of FSGS and GN [1,5,7,10]. Analysis of the podocyte vs. adipose tissue specific expression of genes downstream of PPARγ containing putative or identified PPREs (Figure 3) informs us that these downstream effects in podocytes/glomeruli are likely directed by the PPARγ1 splice variant, distinct from the adipocyte-regulatory γ2 variant.

Since their identification in 1990, PPARγ has been recognized as a nuclear receptor superfamily member, a ligand-dependent transcription factor and a master regulator of adipogenesis and metabolism, which accounts for the insulin sensitizing effects of its agonists or anti-diabetic drugs such as TZDs [63]. While its role in regulating adipogenesis and lipid metabolism in adipose tissue, liver and skeletal muscle is well-characterized, the knowledge of PPARγ-regulated signaling pathways in kidneys and in podocytes is scarce [5–10,25–29,64]. In our previous studies we speculated a cross-talk model between the PPARγ and glucocorticoid receptor and further demonstrated that while pioglitazone could provide proteinuria reducing benefits, it could also enhance the ability of low-dose steroids to reduce proteinuria [6]. This suggested the potential clinical use of these FDA-approved drugs in enabling the reduction of steroid dose, toxicity, and side effects to treat NS. We further translated the se findings and demonstrated the ability of pioglitazone...
approved drugs in enabling the reduction of steroid dose, toxicity, and side effects to treat NS. We further translated these findings and demonstrated the ability of pioglitazone administration to improve clinical outcome in a child with steroid-refractory NS, which has now been extended in other NS patients as well [6,65]. Moreover, we have recently found that targeting PPARγ with a selective modulator, GQ-16, offers an even better therapeutic strategy in NS, by reducing proteinuria and NS-associated side effects with a greater efficacy while providing reduced adipogenic effects than traditional TZDs [24]. However, to understand the proteinuria-reducing podocyte protective effects of PPARγ activation, it is critical to build an understanding of podocyte specific transcriptional activity of PPARγ as the lack of such knowledge is a barrier to modulating PPARγ activity effectively. The existence of two isoforms γ1 and γ2 as a result of different promoter usage and AS further complicates the PPARγ biology [5,30,31]. As a result, γ2 contains 30 additional amino acids at its N terminal, despite a longer γ1 mRNA sequence at its 5'UTR. We found that podocytes as well as glomeruli, express the more ubiquitous form of PPARγ, the γ1 form and not the γ2 form, which is restricted to adipose tissue and liver. Interestingly a few other spliced forms of PPARγ have been discovered in the past few years, which may confer varied functions [32–36]. Approximately 95% of mammalian genes undergo AS that can result in different protein products as well as microRNA sensitivity, mRNA stability, localization, and translation efficiency [66,67]. Moreover, AS is associated with many cellular processes and diseases such as differentiation, cancer, and immunity to name a few [66,68]. Moreover, expression of PPARγ1 and 2 mRNAs and isoforms in adipose tissue, liver, and skeletal muscle is known to be regulated in animal models of obesity, diabetes, and nutrition [69]. As the expression and role of the AS of PPARγ in podocyte biology is unexplored, we performed a landscape analysis of other PPARγ forms, which have been identified mostly in adipose tissues in recent years, including some with dominant negative function [32–37]. We could detect low expression of variants 4, 3, 11, and tORf4, and variant 9 was undetectable in the whole kidney. In podocytes, Var 9 was detectable at very low levels, and these additional variants were barely detectable consistently. We have recently also observed the presence of variant 11 form due to skipping of exon 5 (delta 5) in the WAT, which was particularly reduced with both pioglitazone and GQ-16 [24]. Ligand-mediated PPARγ activation has been shown to induce skipping of exon 5 which by itself lacks ligand-dependent transactivation ability, and thus acts as a dominant negative form of PPARγ [32]. In particular, recent evidence points towards distinct roles of γ1 vs. γ2 variant of PPARγ governing specific and separate gene expression and metabolic functions at different stages in adipocytes [70], as well as between adipocytes and macrophages [38]. In the current study, analysis of the podocyte vs. adipocyte specific expression of genes downstream of PPARγ containing putative or identified PPREs informs us that these downstream effects in podocytes are likely directed by the PPARγ1 splice variant, distinct from the adipocyte-regulatory γ2 variant (Figures 3 and 4). This is also evident from differential gene expression, enrichment and signaling pathways in the podocytes vs. adipocytes. Notably, we found podocyte specific PPRE-containing genes to be functionally enriched in cell–cell junction and cell–cell adhesion, which are known to play critical roles in the maintenance of podocyte structure and function and in its normal physiology [71]. This also suggests that activation of podocyte PPARγ with agonists or selective modulators to drive these pathways is a viable therapeutic option to restore podocyte health during injury. At the same time, we acknowledge the limitations of in silico prediction of PPREs, species-specific differences that may exist in the location and functionality of these PPREs [72], and the involvement of other co-transcription factors that determine cell specificity of PPARγ [38]. Overall, previous evidence indicates that the: (1) activation of PPARγ results in reduction in podocyte injury and proteinuria [1,4–6,12,13], (2) podocyte specific PPARγ KO results in resistance to protection of proteinuria by PPARγ agonists [7,10], and (3) selective modulation of PPARγ enhances proteinuria reducing efficacy with reduced adipogenic potential [24]. Taken together with the findings in the current study suggesting that the podocytes do not express the γ2 form, yet they are
responsive to treatments by PPAR\(\gamma\) agonists, implicate that those new selective modulators can be potentially developed that will be able to distinguish between the two forms, \(\gamma_1\) and \(\gamma_2\), thus forming a basis of novel targeted therapeutic avenues.

PPAR\(\gamma\) also undergoes post-translational modifications and its differential phosphorylation at serine (Ser) 273 is an important determinant of its effect on adipogenesis and insulin sensitivity [47,73,74]. PPAR\(\gamma\) phosphorylation at Ser273 was demonstrated in obesity models and treatment with the PPAR\(\gamma\) agonist dephosphorylates this residue in the adipose tissue. GQ-16, a selective modulator of PPAR\(\gamma\) has been shown to dephosphorylate PPAR\(\gamma\) in an in vitro assay like traditional TZDs [73,74]. Since this site of phosphorylation on Ser273 is encoded by the last codon on exon 4, it remains conserved in major variants, 1 and 2, and several other variants in the current study, except for Var9, which was only detectable in podocytes at very low levels. It should be noted that the relative position is Ser243 in the variants including A1 and A2 exons instead of Ser273 in the B exon. Moreover, our recent findings suggested that relative phosphorylated PPAR\(\gamma\) levels (at Ser273) remained unaltered during glomerular injury and with treatments with pioglitazone and GQ-16 treatments in the glomeruli [24]. These data suggest that while PPAR\(\gamma\)-Ser273 is critical in determining the insulin sensitizing effects of PPAR\(\gamma\) in adipose tissue, it is unlikely to be a major mechanism of regulation in podocytes or glomeruli.

In the present study, we have observed a clear indication of the disparate roles of \(\gamma_1\) vs. \(\gamma_2\) in podocyte vs. adipocyte function and physiology and demonstrated the presence of other AS variants of PPAR\(\gamma\) mRNA in podocytes that would share the 5'UTR with variant 1 (encoding \(\gamma_1\) isoform), although the roles of these other variants in podocytopathies and podocyte differentiation is still unclear. Their detection of differential expression is a challenge as they are observed to be present at too low levels in podocytes (unlike the adipocyte variants). It might be worthwhile to pursue studies in future wherein these variants are overexpressed using reporter plasmids followed by the analysis of their effects on podocyte physiology, actin cytoskeleton and function in the presence of injury causing agents, such as PAN. The demonstration of presence of these variants also warrants their detection in kidney biopsies from patients treated with PPAR\(\gamma\) agonists for diabetic nephropathy or type II diabetes.

In summary, we have shown that podocytes and glomeruli express the variants encoding the major form of PPAR\(\gamma\)1 isoform and do not express the variants encoding the other major form \(\gamma_2\). Moreover, expression of other AS forms of PPAR\(\gamma\) has been detected at very low levels in podocytes which may have implications in its pathophysiology. Future studies directed at developing new selective modulators that can distinguish between the two forms, \(\gamma_1\) and \(\gamma_2\), to enhance beneficial effects and reduce harmful effects of PPAR\(\gamma\) activation has the potential to provide novel targeted therapeutic avenues.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11213455/s1, Figure S1: clusterProfiles generated functional enrichment of all PPRE containing genes detectable in adipocytes and/or podocytes; Figure S2: PPAR\(\gamma\)-Response Element (PPRE) containing Genes in PPARgene dataset and Lemay and Hwang Manuscript detected in podocytes and/or adipocytes; Table S1: PPRE-driven genes from the PPAR-gene dataset, identified in podocyte and adipocyte datasets; Table S2: PPRE-driven genes from Lemay and Hwang manuscript, identified in podocyte and adipocyte datasets; Table S3: PPRE-driven genes in the PPARgene dataset and Lemay and Hwang manuscript

**Author Contributions:** Conceptualization, S.A.; Methodology, S.A., R.G., A.W., D.C., A.S.B. and C.B.; Formal Analysis, C.B., A.W. and S.A.; Investigation, C.B. and S.A.; Resources, S.A.; Data Curation, C.B., A.W. and S.A.; Writing—Original Draft Preparation, C.B. and S.A.; Writing—Review and Editing, S.A., R.G., A.W., D.C., A.S.B. and C.B.; Visualization, C.B. and S.A.; Supervision, S.A.; Project Administration, S.A.; Funding Acquisition, S.A. All authors have read and agreed to the published version of the manuscript.
Funding: This study was supported by the American Heart Association Career Development Award (CDA34110287), funds from Nationwide Children’s Hospital (NCH) and Stony Brook University Renaissance School of Medicine to S.A.

Data Availability Statement: The original contributions presented in the study are included in the article material, further inquiries can be directed to the corresponding author.

Acknowledgments: The authors thank Jeffrey Kopp at the National Institute of Health and Moin Saleem at the University of Bristol for sharing the immortalized human podocyte cell line, and members of the animal resource core at the Abigail Wexner Research Institute, Nationwide Children’s Hospital (NCH).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Agrawal, S.; Guess, A.J.; Benndorf, R.; Smoyer, W.E. Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: Protection from injury and molecular effects. Mol. Pharmacol. 2011, 80, 389–399. [CrossRef] [PubMed]
2. Miglio, G.; Rosa, A.C.; Rattazzi, L.; Grange, C.; Camussi, G.; Fantozzi, R. Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: Proposed mechanisms of action. Br. J. Pharmacol. 2012, 167, 641–653. [CrossRef] [PubMed]
3. Miglio, G.; Rosa, A.C.; Rattazzi, L.; Grange, C.; Collino, M.; Camussi, G.; Fantozzi, R. The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. Br. J. Pharmacol. 2011, 162, 111–125. [CrossRef] [PubMed]
4. Kanjanabuch, T.; Ma, L.J.; Chen, J.; Pozzi, A.; Guan, Y.; Mundel, P.; Fogo, A.B. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 2007, 71, 1232–1239. [CrossRef]
5. Agrawal, S.; Chanley, M.A.; Westbrook, D.; Nie, X.; Kitao, T.; Guess, A.J.; Benndorf, R.; Hidalgo, G.; Smoyer, W.E. Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. Sci. Rep. 2016, 6, 24392. [CrossRef]
6. Henrique, C.; Bollee, G.; Lenoir, O.; Dhaun, N.; Camus, M.; Chipont, A.; Flousseau, K.; Mandet, C.; Yamamoto, M.; Karras, A.; et al. Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor gamma Essential for Resistance to Crescentic GN. J. Am. Soc. Nephrol. 2017, 28, 172–188. [CrossRef]
7. Ma, L.J.; Marcantoni, C.; Linton, M.F.; Fazio, S.; Fogo, A.B. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001, 59, 1899–1910. [CrossRef]
8. Platt, C.; Coward, R.J. Peroxisome proliferator activating receptor-gamma and the podocyte. Nephrol. Dial. Transplant. 2016, 32, 423–433.
9. Sonneveld, R.; Hoenderop, J.G.; Isidori, A.M.; Henique, C.; Dijkman, H.B.; Berden, J.H.; Tharaux, P.L.; van der Vlag, J.; Nijenhuis, T. Sildenafil Prevents Podocyte Injury via PPAR-gamma-Mediated TRPC6 Inhibition. J. Am. Soc. Nephrol. 2017, 28, 1491–1505. [CrossRef]
10. Yang, H.C.; Deleuze, S.; Zuo, Y.; Potthoff, S.A.; Ma, L.J.; Fogo, A.B. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. J. Am. Soc. Nephrol. 2009, 20, 2380–2388. [CrossRef] [PubMed]
11. Yang, H.C.; Ma, L.J.; Ma, J.; Fogo, A.B. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int. 2006, 69, 1756–1764. [CrossRef] [PubMed]
12. Luo, Y.; Yang, H.C.; Potthoff, S.A.; Najafian, B.; Kon, V.; Ma, L.J.; Fogo, A.B. Protective effects of PPARgamma agonist in acute nephrotic syndrome. Nephrol. Dial. Transplant. 2012, 27, 174–181. [CrossRef] [PubMed]
13. Benzing, T. Molecular Design of the Kidney Filtration Barrier. Trans. Am. Clin. Climatol. Assoc. 2020, 131, 125–139.
14. Butt, L.; Unnersjo-Jess, D.; Hohne, M.; Edwards, A.; Binz-Lotter, J.; Reilly, D.; Hahnfeldt, R.; Ziegler, V.; Frenster, K.; Rinschen, M.M.; et al. A molecular mechanism explaining albuminuria in kidney disease. Nat. Metab. 2020, 2, 461–474. [CrossRef]
15. Assady, S.; Wanner, N.; Skorecki, K.L.; Huber, T.B. New Insights into Podocyte Biology in Glomerular Health and Disease. J. Am. Soc. Nephrol. 2017, 28, 1707–1715. [CrossRef]
16. Kerjaschki, D. 2015 Homer W. Smith Award: The Podocyte from Periphery to Center Stage. J. Am. Soc. Nephrol. 2016, 27, 3266–3270. [CrossRef]
17. Siddall, E.C.; Radhakrishnan, J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int. 2012, 82, 635–643. [CrossRef]
18. Araya, C.E.; Wasserfall, C.H.; Brusko, T.M.; Mu, W.; Segal, M.S.; Johnson, R.J.; Garin, E.H. A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephropathy syndrome. Pediatr. Nephrol. 2006, 21, 603–610.
19. Araya, C.; Diaz, L.; Wasserfall, C.; Atkinson, M.; Mu, W.; Johnson, R.; Garin, E. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 2009, 24, 1691–1698. [CrossRef]
20. Agrawal, S.; Zititsky, J.I.; Fornoni, A.; Smoyer, W.E. Dyslipidaemia in nephrotic syndrome: Mechanisms and treatment. Nat. Rev. Nephrol. 2018, 14, 57–70. [CrossRef]
21. The authors thank Jeffrey Kopp at the National Institute of Health and Moin Saleem at the University of Bristol for sharing the immortalized human podocyte cell line, and members of the animal resource core at the Abigail Wexner Research Institute, Nationwide Children’s Hospital (NCH).
22. Kendall, A.G.; Lohmann, R.C.; Dossetor, J.B. Nephrotic syndrome. A hypercoagulable state. *Arch. Intern. Med.* 1971, 127, 1021–1027. [CrossRef] [PubMed]

23. Alkjaersig, N.; Fletcher, A.P.; Narayanan, M.; Robson, A.M. Course and resolution of the coagulopathy in nephrotic children. *Kidney Int.* 1987, 31, 772–780. [CrossRef] [PubMed]

24. Bryant, C.; Rask, G.; Waller, A.P.; Webb, A.; Galdino-Pitta, M.R.; Amato, A.A.; Cianciolo, R.; Govindarajan, R.; Becknell, B.; Kerlin, B.A.; et al. Selective modulator of nuclear receptor PPARGamma with reduced adipogenic potential ameliorates experimental nephrotic syndrome. *iScience* 2022, 10, 104001. [CrossRef]

25. Lefterova, M.I.; Haakonsson, A.K.; Lazar, M.A.; Mandrup, S. PPARGamma and the global map of adipogenesis and beyond. *Trends Endocrinol. Metab.* 2014, 25, 293–302. [CrossRef]

26. Berger, J.P.; Akiyama, T.E.; Meinke, P.T. PPARs: Therapeutic targets for metabolic disease. *Trends Pharmacol. Sci.* 2005, 26, 244–251. [CrossRef]

27. Ahmadian, M.; Suh, J.M.; Hah, N.; Lidelle, C.; Atkins, A.R.; Downes, M.; Evans, R.M. PPARGamma signaling and metabolism: The good, the bad and the future. *Nat. Med.* 2013, 19, 557–566. [CrossRef]

28. Evans, R.M.; Barish, G.D.; Wang, Y.X. PPARs and the complex journey to obesity. *Nat. Med.* 2004, 10, 355–361. [CrossRef]

29. Agrawal, S.; Guess, A.J.; Chanley, M.A.; Smoyer, W.E. Albumin-induced podocyte injury and protection are associated with regulation of COX-2. *Kidney Int.* 2014, 86, 1150–1160. [CrossRef]

30. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K.; Lefebvre, A.M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J.C.; Deeb, S.; et al. The organization, promoter analysis, and expression of the human PPARGamma gene. *J. Biol. Chem.* 1997, 272, 18779–18789. [CrossRef]

31. Mukherjee, R.; Jow, L.; Croston, G.E.; Patermiti, J.R., Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARGamma2 versus PPARGamma1 and activation with retinoid X receptor agonists and antagonists. *J. Biol. Chem.* 1997, 272, 8071–8076. [CrossRef] [PubMed]

32. Aprile, M.; Cataldi, S.; Ambrosio, M.R.; D’Esposito, V.; Lim, K.; Dietrich, A.; Bluher, M.; Savage, D.B.; Formisano, P.; Ciccodicola, A.; et al. PPARGammaDelta5, a Naturally Occurring Dominant-Negative Splice Isoform, Impairs PPARGamma Function and Adipocyte Differentiation. *Cell Rep.* 2018, 25, 1577–1592.e6. [CrossRef] [PubMed]

33. Aprile, M.; Ambrosio, M.R.; D’Esposito, V.; Beguinot, F.; Formisano, P.; Costa, V.; Ciccodicola, A. PPARG in Human Adipogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms. *PPAR Res.* 2014, 2014, 537865. [CrossRef] [PubMed]

34. Chen, Y.; Jimenez, A.R.; Medh, J.D. Identification and regulation of novel PPARGamma splice variants in human THP-1 macrophages. *Biochim. Biophys. Acta* 2006, 1759, 32–43. [CrossRef]

35. Sabatino, L.; Casamassimi, A.; Peluso, G.; Barone, M.V.; Capaccio, D.; Migliore, C.; Bonelli, P.; Pedicini, A.; Febbraro, A.; Ciccodicola, A.; et al. A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. *J. Biol. Chem.* 2005, 280, 26517–26525. [CrossRef]

36. Zhou, J.; Wilson, K.M.; Medh, J.D. Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. *Biochem. Biophys. Res. Commun.* 2002, 293, 274–283. [CrossRef]

37. Mukha, A.; Kalkhoven, E.; van Mil, S.W.C. Splice variants of metabolic nuclear receptors: Relevance for metabolic disease and therapeutic targeting. *Biochem. Biophys. Acta Mol. Basis Dis.* 2021, 1867, 166183. [CrossRef]

38. Lefterova, M.I.; Steger, D.J.; Zhuo, D.; Qatanani, M.; Mullican, S.E.; Tuteja, G.; Manduchi, E.; Grant, G.R.; Lazar, M.A. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. *Mol. Cell. Biol.* 2010, 30, 2078–2089. [CrossRef]

39. Saleem, M.A.; O’Hare, M.J.; Reiser, J.; Coward, R.J.; Inward, C.D.; Farren, T.; Xing, C.Y.; Ni, L.; Mathieson, P.W.; Mundel, P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. *J. Am. Soc. Nephrol.* 2002, 13, 630–638. [CrossRef]

40. Paffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 2001, 29, e45. [CrossRef]

41. Solanki, A.K.; Srivastava, P.; Rahman, B.; Lipschutz, J.H.; Nihalani, D.; Arif, E. The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes. *Int. J. Mol. Sci.* 2019, 21, 274. [CrossRef] [PubMed]

42. Whitehead, A.; Krause, F.N.; Moran, A.; MacCannell, A.D.V.; Scragg, J.L.; McNally, B.D.; Boateng, E.; Murfitt, S.A.; Virtue, S.; Wright, J.; et al. Brown and beige adipose tissue regulate systemic metabolism through a metabolite interorgan signaling axis. *Nat. Commun.* 2021, 12, 1905. [CrossRef]

43. Fang, L.; Zhang, M.; Li, Y.; Liu, Y.; Cui, Q.; Wang, N. PPARGene: A Database of Experimentally Verified and Computationally Predicted PPAR Target Genes. *PPAR Res.* 2016, 2016, 6042162. [CrossRef] [PubMed]

44. Lemay, D.G.; Hwang, D.H. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. *J. Lipid Res.* 2006, 47, 1583–1587. [CrossRef]

45. Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. *OMICS* 2012, 16, 284–287. [CrossRef] [PubMed]

46. Tontonoz, P.; Hu, E.; Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARGamma and 2, a lipid-activated transcription factor. *Cell* 1994, 79, 1147–1156. [CrossRef]
47. Choi, J.H.; Banks, A.S.; Estall, J.L.; Kajimura, S.; Bostrom, P.; Laznik, D.; Ruas, J.L.; Chalmers, M.J.; Kamenecka, T.M.; Bluhm, M.; et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. *Nature* 2010, 466, 451–456. [CrossRef]

48. Ettou, S.; Jung, Y.L.; Miyoshi, T.; Jain, D.; Hiratsuka, K.; Schumacher, V.; Taglienti, M.E.; Morizane, R.; Park, P.J.; Kreidberg, J.A. Epigenetic transcriptional reprogramming by WT1 mediates a repair response during podocyte injury. *Sci. Adv.* 2020, 6, eabb5460. [CrossRef]

49. Eddy, A.A.; Fogo, A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: Evidence and mechanisms of action. *J. Am. Soc. Nephrol.* 2006, 17, 2999–3012. [CrossRef]

50. Kobayashi, N.; Ueno, T.; Ohashi, K.; Yamashita, H.; Takahashi, Y.; Sakamoto, K.; Manabe, S.; Hara, S.; Takishima, Y.; Dan, T.; et al. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated beta1-integrin endocytosis. *Am. J. Physiol. Renal Physiol.* 2015, 308, 614–626. [CrossRef]

51. Cheng, H.; Fan, X.; Guan, Y.; Zent, R.; Harris, R.C. Distinct roles for basal and induced COX-2 in podocyte injury. *J. Am. Soc. Nephrol.* 2009, 20, 1953–1962. [CrossRef] [PubMed]

52. Asanuma, K.; Kim, K.; Oh, J.; Giardino, L.; Chabanis, S.; Faul, C.; Reiser, J.; Mundel, P. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. *J. Clin. Invest.* 2005, 115, 1188–1198. [CrossRef] [PubMed]

53. Ahsan, W. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective. *Curr. Pharm. Des.* 2019, 25, 2540–2554. [CrossRef] [PubMed]

54. Hofmann, C.A.; Colca, J.R. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. *Diabetes Care* 1992, 15, 1075–1078. [CrossRef]

55. Sarafidis, P.A.; Stafylas, P.C.; Georgianos, P.I.; Saratzis, A.N.; Lasaridis, A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. *Am. J. Kidney Dis.* 2010, 55, 835–847. [CrossRef]

56. Buckingham, R.E.; Al-Barazanji, K.A.; Toseland, C.D.; Slaughter, M.; Connor, S.C.; West, A.; Bond, B.; Turner, N.C.; Clapham, J.C. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. *Diabetes* 1998, 47, 1326–1334. [CrossRef]

57. Cha, D.R.; Zhang, X.; Zhang, Y.; Wu, J.; Su, D.; Han, J.Y.; Fang, X.; Yu, B.; Breyer, M.D.; Guan, Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazin attenuates diabetic nephropathy in db/db mice. *Diabetes* 2007, 56, 2036–2045. [CrossRef]

58. Tanimoto, M.; Fan, Q.; Gohda, T.; Shike, T.; Makita, Y.; Tomino, Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. *Metabolism* 2004, 53, 1473–1479. [CrossRef]

59. Calkin, A.C.; Giunti, S.; Jandeleit-Dahm, K.A.; Allen, T.J.; Cooper, M.E.; Thomas, M.C. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. *Nephrol. Dial. Transplant.* 2006, 21, 2399–2405. [CrossRef]

60. Chinetti, G.; Griglio, S.; Antonucci, M.; Torra, I.P.; Delerive, P.; Majd, Z.; Fruchart, J.C.; Chapman, J.; Najib, J.; Staels, B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. *J. Biol. Chem.* 1998, 273, 25573–25580. [CrossRef]

61. Bouhlel, M.A.; Derudas, B.; Rigamonti, E.; Dievart, R.; Brozek, J.; Haulon, S.; Zawadzki, C.; Jude, B.; Torpier, G.; Marx, N.; et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. *Cell Metab.* 2007, 6, 137–143. [CrossRef] [PubMed]

62. Straus, D.S.; Glass, C.K. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. *Trends Immunol.* 2007, 28, 551–558. [CrossRef]

63. Heikkinen, S.; Auwerx, J.; Argmann, C.A. PPARgamma in human and mouse physiology. *Biochim. Biophys. Acta* 2007, 1771, 999–1013. [CrossRef] [PubMed]

64. Afzal, S.; Sattar, M.A.; Johns, E.J.; Eseyin, O.A. Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats. *PLoS ONE* 2020, 15, e0229803. [CrossRef] [PubMed]

65. Hunley, T.E.; Hidalgo, G.; Ng, K.H.; Shirai, Y.; Miura, K.; Beng, H.M.; Wu, Q.; Hattori, M.; Smoyer, W.E. Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. *Pediatr. Nephrol.* 2022, 1–12. [CrossRef]

66. Scotti, M.M.; Swanson, M.S. RNA mis-splicing in disease. *Nat. Rev. Genet.* 2016, 17, 19–32. [CrossRef]

67. Blijlevens, M.; Li, J.; van Beusechem, V.W. Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities. *Int. J. Mol. Sci.* 2021, 22, 5110. [CrossRef]

68. Montes, M.; Sanford, B.L.; Comiskey, D.F.; Chandler, D.S. RNA Splicing and Disease: Animal Models to Therapies. *Trends Genet.* 2019, 35, 68–87. [CrossRef]

69. Vidal-Puig, A.; Jimenez-Linan, M.; Lowell, B.B.; Hamann, A.; Hu, E.; Spiegelman, B.; Flier, J.S.; Moller, D.E. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. *J. Clin. Invest.* 1996, 97, 2553–2561. [CrossRef]

70. Hu, W.; Jiang, C.; Kim, M.; Xiao, Y.; Richter, H.J.; Guan, D.; Zhu, K.; Kruesen, B.M.; Roberts, A.N.; Miller, J.; et al. Isoform-specific functions of PPARgamma in gene regulation and metabolism. *Genes Dev.* 2020, 34, 300–312. [CrossRef]

71. Lennon, R.; Randles, M.J.; Humphries, M.J. The importance of podocyte adhesion for a healthy glomerulus. *Front. Endocrinol.* 2014, 5, 160.
72. Schmidt, S.F.; Jorgensen, M.; Chen, Y.; Nielsen, R.; Sandelin, A.; Mandrup, S. Cross species comparison of C/EBPalpha and PPARgamma profiles in mouse and human adipocytes reveals interdependent retention of binding sites. *BMC Genom.* 2011, 12, 152. [CrossRef] [PubMed]

73. Amato, A.A.; Rajagopalan, S.; Lin, J.Z.; Carvalho, B.M.; Figueira, A.C.; Lu, J.; Ayers, S.D.; Mottin, M.; Silveira, R.L.; Souza, P.C.; et al. GQ-16, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, promotes insulin sensitization without weight gain. *J. Biol. Chem.* 2012, 287, 28169–28179. [CrossRef] [PubMed]

74. Coelho, M.S.; de Lima, C.L.; Royer, C.; Silva, J.B.; Oliveira, F.C.; Christ, C.G.; Pereira, S.A.; Bao, S.N.; Lima, M.C.; Pitta, M.G.; et al. GQ-16, a TZD-Derived Partial PPARgamma Agonist, Induces the Expression of Thermogenesis-Related Genes in Brown Fat and Visceral White Fat and Decreases Visceral Adiposity in Obese and Hyperglycemic Mice. *PLoS ONE* 2016, 11, e0154310. [CrossRef]